LIPLASOME PHARMA
LiPlasome is a Danish privately owned biotech company focusing on oncology. The LiPlasome technology provides a liplasomal reformulation of the most used anticancer drugs on the market like Cispaltin -> LiPlaCisรยฎ, Oxaliplatin -> LiPloxa. The aim is to provide more effective treatment to cancer patients with fewer side effects.
LIPLASOME PHARMA
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2002-01-01
Address:
Vejle, Syddanmark, Denmark
Country:
Denmark
Website Url:
http://www.liplasome.com
Total Employee:
11+
Status:
Active
Contact:
45 88 70 80 20
Total Funding:
8.01 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Euro Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Sectigo SSL Sectigo Domain SSL LiteSpeed
Similar Organizations
Investors List
Incuba Venture
Incuba Venture investment in Series B - LiPlasome Pharma
BankInvest Biomedical Venture
BankInvest Biomedical Venture investment in Series B - LiPlasome Pharma
Vecata
Vecata investment in Series B - LiPlasome Pharma
Official Site Inspections
http://www.liplasome.com
- Host name: linux7.curanet.dk
- IP address: 185.21.40.99
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "LiPlasome Pharma"
Company Information - RocketReach
LiPlasome is a Danish privately owned biotech company focusing on oncology. The LiPlasome technology provides a liplasomal reformulation of the most used anticancer drugs on the โฆSee details»
LiPlasome Pharma - Overview, News & Similar companies
Who is LiPlasome Pharma. LiPlasome is a Danish privately owned biotech company focusing on oncology. The LiPlasome technology provides a liplasomal reformulation of the most used โฆSee details»
LiPlasome Pharma Company Profile 2024: Valuation, โฆ
LiPlasome Pharma General Information Description. Developer of drug delivery technologies designed to offer anticancer drugs and pro-drugs. The โฆSee details»
Vecata A/S - LiPlasome - Bagger-Sorensen
LiPlasome Pharma Plc. is a Danish biotech company focused on cancer therapy. The company has developed a technology based on incapsulation of chemotherapy in liposomes (fatty โฆSee details»
LiPlasome Pharma - Products, Competitors, Financials, Employees ...
LiPlasome Pharma was founded in 2001. Where is LiPlasome Pharma's headquarters? LiPlasome Pharma's headquarters is located at Diplomvej 378, Kongens Lyngby. What is โฆSee details»
LiPlasome Pharma Company Profile - Office Locations ... - Craft
LiPlasome Pharma has 5 employees at their 1 location and $8.01 m in total funding,. See insights on LiPlasome Pharma including office locations, competitors, revenue, financials, executives, โฆSee details»
Liplasome Pharma ApS - Drug pipelines, Patents, Clinical trials
Nov 1, 2024 Abstract LiPlaCis is a novel liposomal formulation of cisplatin, designed to be specifically degraded by secretory phospholipase A2 (sPLA2) which is over-expressed in โฆSee details»
LiPlasome Pharma - Crunchbase
LiPlasome, a biotech company focused on oncology, provides a liplasomal reformulation of anticancer drugs on the market.See details»
LiPlasome Pharma A/S:Company Profile & Technical โฆ
LiPlasome Pharma is a company that provides Chemotherapy, Drug, Cancer and more. LiPlasome Pharma is headquartered in DK ND. LiPlasome Pharma was founded in 2001. โฆSee details»
LiPlasome - Company Profile - Tracxn
LiPlasome - Developer of liposomal formulation for cancer treatment. Raised a total funding of $875K over 2 rounds from 1 investor. Valued at $21.4M. Founded by Kent Jorgensen and โฆSee details»
LiPlasome Pharma - VentureRadar
Find out more about LiPlasome Pharma including the VentureRadar Innovation and Growth scores, Similar Companies and more. All; Ranked; Organisation Names; Apps and Links. โฆSee details»
LiPlasome Pharma - Funding, Financials, Valuation & Investors
LiPlasome, a biotech company focused on oncology, provides a liplasomal reformulation of anticancer drugs on the market.See details»
LiPlasome Pharma AS - In Vivo
Jun 1, 2003 LiPlasome Pharma AS was established in January 2001 to commercialize its novel lipid-based drug delivery platform based on engineered liposomes dubbed liplasomes. โฆSee details»
LiPlasome Pharma ApS Asset Profile | Preqin
In 2012, LiPlasome Pharma ApS raised venture funding from new investor East West Capital Partners. LiPlasome offers a lipid-based drug delivery platform that uses technology to provide โฆSee details»
LiPlasome Pharma A/S (LiPlasome Pharma A/S) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ โฆ
้กนไธ LiPlasome Pharma A/S ็ธๅ ณ็ๆ็ฎ๏ผๅป่ฏ๏ผ 2004-11-01 · Molecular cancer therapeutics 2ๅบ · ๅปๅญฆ Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel โฆSee details»
LiPlasome | Funding & Investors - Tracxn
List of Funding Rounds and Investors of LiPlasome. List of Funding Rounds and Investors of LiPlasome Toggle navigation. Solutions. By Investment Industry. Venture Capital Funds โฆSee details»
Lipid encapsulated cisplatin - Allarity Therapeutics /LiPlasome โฆ
Jul 5, 2023 A lipid encapsulated formulation of cisplatin, called LiPlaCis®, is being developed by LiPlasome Pharma and Smerud Medical Research (licensed from Oncology Lipid โฆSee details»
LiPlasome Pharma - Tech Stack, Apps, Patents & Trademarks
The intellectual property of LiPlasome Pharma includes 2 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Additionally, โฆSee details»
Lipid encapsulated oxaliplatin - LiPlasome Pharma - AdisInsight
A lipid encapsulated formulation of oxaliplatin, designated as LiPloxa, is being developed by LiPlasome Pharma, for the treatment of cancer, using its Lipid encapsulated oxaliplatin - โฆSee details»
Progress in antileishmanial drugs: Mechanisms, challenges, and ...
3 days ago Leishmaniasis, a neglected tropical disease caused by Leishmania parasites, continues to pose global health challenges. Current treatments face issues like resistance, โฆSee details»